A personalized approach for superior sensitivity and accuracy

Amyloidosis is the buildup of abnormal misfolded proteins in the organs. The disease can be systemic and life-threatening, frequently affecting the kidneys, heart, or other vital organs. At least 36 different proteins cause amyloidosis, and the underlying pathogenesis of each type is unique.

Mayo Clinic’s amyloid protein identification methodology is considered the gold standard because of the high sensitivity and accuracy with which it types amyloid proteins in paraffin-embedded specimens. By combining focused laser microdissection (LMD) of Congo redpositive amyloid plaques with the analytical power of liquid chromatography-tandem mass spectrometry (LC-MS/MS)-based proteomic analysis, LC-MS/MS identifies the amyloid type with 100% specificity and 98% sensitivity—a major advancement from the widely used methods of the past.

For example, immunohistochemistry (IHC) delivers lower sensitivity and just 40–80% specificity. In addition, typical IHC panels detect only three types of amyloidosis, which risks failing to identify the myriad of other amyloid types that together account for about 10% of amyloidosis patients.

Which test should I order?

How an ex-NFL Linebacker Overcame his Greatest Opponent, Amylodosis

Matt Millen, ex-pro NFL player, who played on four Super Bowl-winning teams underwent a nearly six-year medical journey in search for answers. Finally, he was diagnosed with amyloidosis using a new testing methodology at Mayo Clinic.

Learn more about how to order this evaluation at your institution.

Additional resources

Current status of laboratory testing of plasma-cell neoplasms: a case-based approach

The overall objective of this program is to fill the knowledge gap faced by practicing hematologists, oncologists, and hematopathologists due to rapid advancements in the laboratory diagnosis and elucidation of prognostic markers of plasma cell proliferative neoplasms.